Clinical Trial Update: QTc Study GSK573719+GW642444 [Phase 1]

View source ↗

Summary

A completed Phase 1 clinical trial update. The study evaluated the QTc effects of two GSK compounds, GSK573719 and GW642444, in patients with chronic obstructiv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK573719
• GW642444 (GW642444)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED